You are here: Home » Companies » News
Business Standard

Glenmark receives final nod from USFDA for drug to treat chronic angina

The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths

Topics
Glenmark Pharmaceuticals | USFDA

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals

on Tuesday said it has received final nod from the US health regulator for its Ranolazine extended-release tablets used for treatment of chronic angina.

Inc has been granted final approval by the United States Food & Drug Administration (USFDA) for Ranolazine extended-release tablets in the strengths of 500 mg and 1,000 mg, the company said in a statement.

The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths, it added.

According to IQVIA sales data for the 12-month period ended May 2019, Ranexa extended-release tablets, 500 mg and 1,000 mg market (which includes brand and all available therapeutic equivalents) achieved annual sales of around $929 million, Glenmark said.

The company's current portfolio consists of 158 products authorised for distribution in the US marketplace and 57 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.

Ranolazine is used to treat chronic angina.

Shares of were trading at Rs 448.25 per scrip on BSE, up 2.63 per cent from the previous close.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 09 2019. 14:00 IST
RECOMMENDED FOR YOU
.